A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

3,038

Participants

Timeline

Start Date

August 10, 2022

Primary Completion Date

August 23, 2027

Study Completion Date

August 23, 2027

Conditions
Herpes Zoster
Interventions
BIOLOGICAL

HZ/su vaccine

No study intervention is administered in this extension study. Participants received the HZ/su vaccine administered in the ZOSTER-049 (NCT02723773), ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) primary studies. In order to assess the persistence of immune responses, participants provide blood samples at Day 1 and yearly from Month 12 until Month 48 in the current ZOSTER-101 study, according to their study group assignment. In case of a suspected HZ case diagnosis in any of the participants, clinical specimens from HZ lesions (3 replicate samples, collected on the same day, per participant) are collected to confirm the diagnosis of HZ by Polymerase Chain Reaction (PCR)

Trial Locations (107)

112

GSK Investigational Site, Taipei

333

GSK Investigational Site, Taoyuan

2145

GSK Investigational Site, Westmead

2502

GSK Investigational Site, Warrawong

3220

GSK Investigational Site, Geelong

8025

GSK Investigational Site, Barcelona

10002

GSK Investigational Site, Taipei

10787

GSK Investigational Site, Berlin

13619

GSK Investigational Site, Tallinn

15236

GSK Investigational Site, Pittsburgh

16132

GSK Investigational Site, Genoa

17491

GSK Investigational Site, Peralada( Girona)

19300

GSK Investigational Site, Rosiers-d'Égletons

20127

GSK Investigational Site, Milan

20520

GSK Investigational Site, Turku

21075

GSK Investigational Site, Elkridge

22143

GSK Investigational Site, Hamburg

22415

GSK Investigational Site, Hamburg

28040

GSK Investigational Site, Marid

28046

GSK Investigational Site, Madrid

28100

GSK Investigational Site, Pori

28209

GSK Investigational Site, Charlotte

28222

GSK Investigational Site, Majadahonda( Madrid

28500

GSK Investigational Site, Vic

28601

GSK Investigational Site, Hickory

33100

GSK Investigational Site, Tampere

34000

GSK Investigational Site, Durango

37620

GSK Investigational Site, Bristol

39112

GSK Investigational Site, Magdeburg

40447

GSK Investigational Site, Taichung

45355

GSK Investigational Site, Essen

45359

GSK Investigational Site, Essen

46020

GSK Investigational Site, Valencia

47574

GSK Investigational Site, Goch

49000

GSK Investigational Site, Angers

49610

GSK Investigational Site, Mûrs-Erigné

50106

GSK Investigational Site, Tartu

51069

GSK Investigational Site, Cologne

53000

GSK Investigational Site, Laval

55116

GSK Investigational Site, Mainz

58455

GSK Investigational Site, Witten

60100

GSK Investigational Site, Seinäjoki

63003

GSK Investigational Site, Clermont-Ferrand

65439

GSK Investigational Site, Flörsheim

67100

GSK Investigational Site, Kokkola

69469

GSK Investigational Site, Weinheim

78229

GSK Investigational Site, San Antonio

84106

GSK Investigational Site, Salt Lake City

85020

GSK Investigational Site, Phoenix

88239

GSK Investigational Site, Wangen

90220

GSK Investigational Site, Oulu

91126

GSK Investigational Site, Rednitzhembach

94574

GSK Investigational Site, Wallerfing

30150-320

GSK Investigational Site, Belo Horizonte

80069-900

GSK Investigational Site, Curitiba

04266-010

GSK Investigational Site, São Paulo

05403-000

GSK Investigational Site, São Paulo

V5Z 1M9

GSK Investigational Site, Vancouver

V8R 6R3

GSK Investigational Site, Victoria

B3K 6R8

GSK Investigational Site, Halifax

B2N1L2

GSK Investigational Site, Truro

M4S 1Y2

GSK Investigational Site, Toronto

M9W 4L6

GSK Investigational Site, Toronto

J7J 2K8

GSK Investigational Site, Mirabel

G1E 7G9

GSK Investigational Site, Québec

G1W 4R4

GSK Investigational Site, Québec

J1J 2G2

GSK Investigational Site, Sherbrooke

612 00

GSK Investigational Site, Brno

370 05

GSK Investigational Site, České Budějovice

500 05

GSK Investigational Site, Hradec Králové

02230

GSK Investigational Site, Espoo

00100

GSK Investigational Site, Helsinki

00930

GSK Investigational Site, Helsinki

04400

GSK Investigational Site, Järvenpää

01097

GSK Investigational Site, Dresden

09599

GSK Investigational Site, Freiberg

000000

GSK Investigational Site, Shatin

810-0021

GSK Investigational Site, Fukuoka

812-0025

GSK Investigational Site, Fukuoka

813-8588

GSK Investigational Site, Fukuoka

816-0864

GSK Investigational Site, Fukuoka

224-8503

GSK Investigational Site, Kanagawa

142-8666

GSK Investigational Site, Tokyo

425-707

GSK Investigational Site, Ansan

420-767

GSK Investigational Site, Bucheon-si

400-711

GSK Investigational Site, Incheon

220-701

GSK Investigational Site, Kangwon-do

150-950

GSK Investigational Site, Seoul

152-703

GSK Investigational Site, Seoul

08550

GSK Investigational Site, Balenyà (Barcelona)

08035

GSK Investigational Site, Barcelona

08540

GSK Investigational Site, Centelles (Barcelona)

08430

GSK Investigational Site, La Roca del Vallès

SE-506 30

GSK Investigational Site, Borås

SE-413 45

GSK Investigational Site, Gothenburg

Unknown

GSK Investigational Site, Karlskrona

GSK Investigational Site, Stockholm

SE-58758

GSK Investigational Site, Linköping

SE-211 52

GSK Investigational Site, Malmo

SE-703 62

GSK Investigational Site, Örebro

SE-194 61

GSK Investigational Site, Upplands Vasby

SE-751 85

GSK Investigational Site, Uppsala

PR7 7NA

GSK Investigational Site, Buckshaw Village, Chorley

BA15 1DQ

GSK Investigational Site, Bradford-on-Avon

BT7 2EB

GSK Investigational Site, Belfast

BT42 4JP

GSK Investigational Site, Broughshane

L22 0LG

GSK Investigational Site, Liverpool

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY